Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial.
Adenosine Monophosphate
/ administration & dosage
Aged
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Humans
Infusions, Intravenous
Injections, Intravenous
Male
Middle Aged
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors
/ administration & dosage
Prasugrel Hydrochloride
/ administration & dosage
Prospective Studies
Purinergic P2Y Receptor Antagonists
/ administration & dosage
ST Elevation Myocardial Infarction
/ metabolism
Tirofiban
/ administration & dosage
Cangrelor
Platelet aggregation
Prasugrel
Primary PCI
Tirofiban
Journal
Journal of cardiovascular translational research
ISSN: 1937-5395
Titre abrégé: J Cardiovasc Transl Res
Pays: United States
ID NLM: 101468585
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
18
10
2019
accepted:
10
02
2020
pubmed:
26
2
2020
medline:
27
11
2021
entrez:
26
2
2020
Statut:
ppublish
Résumé
Antithrombotic therapy is a critical component of the management of ST-elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (PCI). Rapid and profound inhibition of platelet reactivity has been shown to mitigate the ischemic risks and improve myocardial salvage. High residual platelet reactivity (HRPR) has been reported up to 4 or 6 h after loading dose of prasugrel or ticagrelor; therefore, multiple alternative strategies, including crushed or chewed oral tables or intravenous agents, have been investigated to provide a more rapid and sustained inhibition of platelet function and bridge the initial treatment gap. The FABOLUS FASTER is the first investigator-initiated, multicentre, open-label, prospective, randomized study to directly compare the pharmacodynamics effects of cangrelor, tirofiban, chewed or integer prasugrel. This study will add new insights in the management of antiplatelet therapy in patients with STEMI undergoing primary PCI and might be hypothesis-generating for future clinical trials in this field. The trial is registered on clinicaltrials.gov NCT02978040, and EudraCT 2017-001065-24.
Identifiants
pubmed: 32096064
doi: 10.1007/s12265-020-09969-4
pii: 10.1007/s12265-020-09969-4
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Purinergic P2Y Receptor Antagonists
0
Adenosine Monophosphate
415SHH325A
cangrelor
6AQ1Y404U7
Prasugrel Hydrochloride
G89JQ59I13
Tirofiban
GGX234SI5H
Banques de données
ClinicalTrials.gov
['NCT02978040']
EudraCT
['2017-001065-24']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
110-119Références
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., et al. (2018). 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 39(2), 119–177. https://doi.org/10.1093/eurheartj/ehx393 .
doi: 10.1093/eurheartj/ehx393
pubmed: 28886621
Neumann, F. J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., et al. (2019). 2018 ESC/EACTS guidelines on myocardial revascularization. European Heart Journal, 40(2), 87–165. https://doi.org/10.1093/eurheartj/ehy394 .
doi: 10.1093/eurheartj/ehy394
pubmed: 30165437
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J. P., Costa, F., Jeppsson, A., et al. (2018). 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 39(3), 213–260. https://doi.org/10.1093/eurheartj/ehx419 .
doi: 10.1093/eurheartj/ehx419
pubmed: 28886622
Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., et al. (2016). 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Journal of the American College of Cardiology, 67(10), 1235–1250. https://doi.org/10.1016/j.jacc.2015.10.005 .
doi: 10.1016/j.jacc.2015.10.005
pubmed: 26498666
Davi, G., & Patrono, C. (2007). Platelet activation and atherothrombosis. The New England Journal of Medicine, 357(24), 2482–2494. https://doi.org/10.1056/NEJMra071014 .
doi: 10.1056/NEJMra071014
pubmed: 18077812
Gargiulo, G., Moschovitis, A., Windecker, S., & Valgimigli, M. (2016). Developing drugs for use before, during and soon after percutaneous coronary intervention. Expert Opinion on Pharmacotherapy, 17(6), 803–818. https://doi.org/10.1517/14656566.2016.1145666 .
doi: 10.1517/14656566.2016.1145666
pubmed: 26800365
Alexopoulos, D., Xanthopoulou, I., Gkizas, V., Kassimis, G., Theodoropoulos, K. C., Makris, G., et al. (2012). Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circulation. Cardiovascular Interventions, 5(6), 797–804. https://doi.org/10.1161/CIRCINTERVENTIONS.112.972323 .
doi: 10.1161/CIRCINTERVENTIONS.112.972323
pubmed: 23169985
Parodi, G., Valenti, R., Bellandi, B., Migliorini, A., Marcucci, R., Comito, V., et al. (2013). Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study. Journal of the American College of Cardiology, 61(15), 1601–1606. https://doi.org/10.1016/j.jacc.2013.01.024 .
doi: 10.1016/j.jacc.2013.01.024
pubmed: 23500251
Valgimigli, M., Tebaldi, M., Campo, G., Gambetti, S., Bristot, L., Monti, M., et al. (2012). Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC. Cardiovascular Interventions, 5(3), 268–277. https://doi.org/10.1016/j.jcin.2012.01.006 .
doi: 10.1016/j.jcin.2012.01.006
pubmed: 22440491
Alexopoulos, D., Barampoutis, N., Gkizas, V., Vogiatzi, C., Tsigkas, G., Koutsogiannis, N., et al. (2016). Crushed versus integral tablets of ticagrelor in ST-segment elevation myocardial infarction patients: a randomized pharmacokinetic/pharmacodynamic study. Clinical Pharmacokinetics, 55(3), 359–367. https://doi.org/10.1007/s40262-015-0320-0 .
doi: 10.1007/s40262-015-0320-0
pubmed: 26315810
Asher, E., Frydman, S., Katz, M., Regev, E., Sabbag, A., Mazin, I., et al. (2017). Chewing versus swallowing ticagrelor to accelerate platelet inhibition in acute coronary syndrome - the CHEERS study. For the PLATIS (platelets and thrombosis in Sheba) study group. Thrombosis and Haemostasis, 117(4), 727–733. https://doi.org/10.1160/TH16-09-0728 .
doi: 10.1160/TH16-09-0728
pubmed: 28150850
Asher, E., Tal, S., Mazin, I., Abu-Much, A., Sabbag, A., Katz, M., et al. (2017). Effect of chewing vs swallowing ticagrelor on platelet inhibition in patients with ST-segment elevation myocardial infarction: a randomized clinical trial. JAMA Cardiology, 2(12), 1380–1384. https://doi.org/10.1001/jamacardio.2017.3868 .
doi: 10.1001/jamacardio.2017.3868
pubmed: 29071332
pmcid: 5814990
Parodi, G., Xanthopoulou, I., Bellandi, B., Gkizas, V., Valenti, R., Karanikas, S., et al. (2015). Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. Journal of the American College of Cardiology, 65(5), 511–512. https://doi.org/10.1016/j.jacc.2014.08.056 .
doi: 10.1016/j.jacc.2014.08.056
pubmed: 25660931
Rollini, F., Franchi, F., Hu, J., Kureti, M., Aggarwal, N., Durairaj, A., et al. (2016). Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study. Journal of the American College of Cardiology, 67(17), 1994–2004. https://doi.org/10.1016/j.jacc.2016.02.045 .
doi: 10.1016/j.jacc.2016.02.045
pubmed: 27012781
Serenelli, M., Pavasini, R., Vitali, F., Tonet, E., Bilotta, F., Parodi, G., et al. (2019). Efficacy and safety of alternative oral administrations of P2Y12-receptor inhibitors: systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 17(6), 944–950. https://doi.org/10.1111/jth.14434 .
doi: 10.1111/jth.14434
pubmed: 30884109
Venetsanos, D., Sederholm Lawesson, S., Swahn, E., & Alfredsson, J. (2017). Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: the inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial. Thrombosis Research, 149, 88–94. https://doi.org/10.1016/j.thromres.2016.10.013 .
doi: 10.1016/j.thromres.2016.10.013
pubmed: 27773347
Valgimigli, M., Biondi-Zoccai, G., Tebaldi, M., van’t Hof, A. W., Campo, G., Hamm, C., et al. (2010). Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. European Heart Journal, 31(1), 35–49. https://doi.org/10.1093/eurheartj/ehp376 .
doi: 10.1093/eurheartj/ehp376
pubmed: 19755402
Akers, W. S., Oh, J. J., Oestreich, J. H., Ferraris, S., Wethington, M., & Steinhubl, S. R. (2010). Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. Journal of Clinical Pharmacology, 50(1), 27–35. https://doi.org/10.1177/0091270009344986 .
doi: 10.1177/0091270009344986
pubmed: 19779037
Angiolillo, D. J., Schneider, D. J., Bhatt, D. L., French, W. J., Price, M. J., Saucedo, J. F., et al. (2012). Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. Journal of Thrombosis and Thrombolysis, 34(1), 44–55. https://doi.org/10.1007/s11239-012-0737-3 .
doi: 10.1007/s11239-012-0737-3
pubmed: 22569899
Storey, R. F., Wilcox, R. G., & Heptinstall, S. (2002). Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets, 13(7), 407–413. https://doi.org/10.1080/0953710021000024402 .
doi: 10.1080/0953710021000024402
pubmed: 12487788
Storey, R. F., Oldroyd, K. G., & Wilcox, R. G. (2001). Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thrombosis and Haemostasis, 85(3), 401–407.
doi: 10.1055/s-0037-1615596
Greenbaum, A. B., Grines, C. L., Bittl, J. A., Becker, R. C., Kereiakes, D. J., Gilchrist, I. C., et al. (2006). Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. American Heart Journal, 151(3), 689 e681–689 e610. https://doi.org/10.1016/j.ahj.2005.11.014 .
doi: 10.1016/j.ahj.2005.11.014
Bhatt, D. L., Lincoff, A. M., Gibson, C. M., Stone, G. W., McNulty, S., Montalescot, G., et al. (2009). Intravenous platelet blockade with cangrelor during PCI. The New England Journal of Medicine, 361(24), 2330–2341. https://doi.org/10.1056/NEJMoa0908629 .
doi: 10.1056/NEJMoa0908629
pubmed: 19915222
Harrington, R. A., Stone, G. W., McNulty, S., White, H. D., Lincoff, A. M., Gibson, C. M., et al. (2009). Platelet inhibition with cangrelor in patients undergoing PCI. The New England Journal of Medicine, 361(24), 2318–2329. https://doi.org/10.1056/NEJMoa0908628 .
doi: 10.1056/NEJMoa0908628
pubmed: 19915221
Angiolillo, D. J., Rollini, F., Storey, R. F., Bhatt, D. L., James, S., Schneider, D. J., et al. (2017). International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation, 136(20), 1955–1975. https://doi.org/10.1161/CIRCULATIONAHA.117.031164 .
doi: 10.1161/CIRCULATIONAHA.117.031164
pubmed: 29084738
Franchi, F., Rollini, F., Rivas, A., Wali, M., Briceno, M., Agarwal, M., et al. (2019). Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation, 139(14), 1661–1670. https://doi.org/10.1161/CIRCULATIONAHA.118.038317 .
doi: 10.1161/CIRCULATIONAHA.118.038317
pubmed: 30630341
Vaduganathan, M., Harrington, R. A., Stone, G. W., Deliargyris, E. N., Steg, P. G., Gibson, C. M., et al. (2017). Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb/IIIa inhibitors: an exploratory analysis from the CHAMPION trials. JAMA Cardiology, 2(2), 127–135. https://doi.org/10.1001/jamacardio.2016.4556 .
doi: 10.1001/jamacardio.2016.4556
pubmed: 27902833
Sibbing, D., Aradi, D., Alexopoulos, D., Ten Berg, J., Bhatt, D. L., Bonello, L., et al. (2019). Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC. Cardiovascular Interventions, 12(16), 1521–1537. https://doi.org/10.1016/j.jcin.2019.03.034 .
doi: 10.1016/j.jcin.2019.03.034
pubmed: 31202949
Sibbing, D., Braun, S., Morath, T., Mehilli, J., Vogt, W., Schomig, A., et al. (2009). Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. Journal of the American College of Cardiology, 53(10), 849–856. https://doi.org/10.1016/j.jacc.2008.11.030 .
doi: 10.1016/j.jacc.2008.11.030
pubmed: 19264241
Farid, N. A., McIntosh, M., Garofolo, F., Wong, E., Shwajch, A., Kennedy, M., et al. (2007). Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 21(2), 169–179. https://doi.org/10.1002/rcm.2813 .
doi: 10.1002/rcm.2813
pubmed: 17154350
Bulluck, H., Dharmakumar, R., Arai, A. E., Berry, C., & Hausenloy, D. J. (2018). Cardiovascular magnetic resonance in acute ST-segment-elevation myocardial infarction: recent advances, controversies, and future directions. Circulation, 137(18), 1949–1964. https://doi.org/10.1161/CIRCULATIONAHA.117.030693 .
doi: 10.1161/CIRCULATIONAHA.117.030693
pubmed: 29712696
pmcid: 5933067
Ibanez, B., Aletras, A. H., Arai, A. E., Arheden, H., Bax, J., Berry, C., et al. (2019). Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC scientific expert panel. Journal of the American College of Cardiology, 74(2), 238–256. https://doi.org/10.1016/j.jacc.2019.05.024 .
doi: 10.1016/j.jacc.2019.05.024
pubmed: 31296297
pmcid: 7363031
Gragnano, F., Spedicato, V., Frigoli, E., Gargiulo, G., Di Maio, D., Fimiani, F., et al. (2019). ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. Journal of Electrocardiology, 57, 44–54. https://doi.org/10.1016/j.jelectrocard.2019.08.045 .
doi: 10.1016/j.jelectrocard.2019.08.045
pubmed: 31491602